Dublin, Dec. 07, 2017 (GLOBE NEWSWIRE) -- The "Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis" report has been added to Research and Markets' offering.
The report Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis provides an introduction to dermatology, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications. Disease classification and methods of diagnosis are also provided.
Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 types of dermatological conditions are thought to exist, ranging from the autoimmune disorder psoriasis to the very common condition acne vulgaris. The scope of dermatological disorders is diverse in terms of severity and clinical presentation, and if a condition is not sufficiently kept under control, it can significantly impair the patient's quality of life. For example, patients with severe atopic dermatitis (the most common form of eczema) may experience mobility impairments and debilitating itching, which may interfere with daily activities. Furthermore, most dermatological conditions are visible, and as such can have a profound impact on patient confidence.
There are 850 products in the dermatology pipeline with a disclosed stage of development, but the majority of these drugs are at an early stage of development. Some 42% of the pipeline is in the Preclinical stage, while 14% is in the discovery stage. However, 32% of the pipeline is in clinical development, but only 3% are in the Pre-registration stage and less than half are novel.
Four drugs that were approved for psoriasis are Cosentyx, Otezla, Eucrisa and Taltz. The most notable of the four are Cosentyx and Otezla, which were approved in 2015 and 2014, respectively, and are forecast to generate $3.8 billion and $2.7 billion from the therapy area in 2023, respectively. The two most recently approved psoriasis treatments, Taltz and Eucrisa, are not expected to achieve the same level of commercial success as Cosentyx or Otezla because they are entering a market that is already saturated with entrenched competitors that have reduced the level of unmet need.
Dermatology therapy area is dominated by top 20 pharma companies. In 2016 the most commercially successful companies in the therapy area were Johnson & Johnson, AbbVie, Amgen, Novartis and Pfizer. Across the forecast period these companies will continue to generate high revenue, but the companies will all see their market shares change.
In depth, this report provides the following:
- Provides an overview of the dermatology marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
- Analyzes the dermatology pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: atopic dermatitis, acne vulgaris and psoriasis.
- Presents forecast projections to 2022 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players are provided.
- Assesses the company landscape in dermatology, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area composes a large proportion of each company's pipeline portfolio and total revenues.
Scope:
- Global revenue from the dermatology market is forecast to increase from $19.8 billion in 2016 to $36.6 billion in 2023, at a compound annual growth rate of 9.13%. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
- What are the leading companies in terms of market share?
- Which companies are forecast to experience the largest growth in market share?
- Which companies rely heavily on revenue derived from antibacterial drugs?
- How will the market respond to recent approvals?
- Will generics and biosimilars have a significant impact on the market over the forecast period?
- What class of drugs dominate the market?
- What molecular targets are most popular in the pipeline?
- What are the commercial prospects for the most promising late-stage products?
Key Topics Covered:
1 Table of Contents
2 Introduction
2.1 Therapy Area Introduction
2.2 Symptoms
2.3 Etiology and Pathophysiology
2.3.1 Atopic Dermatitis
2.3.2 Acne Vulgaris
2.3.3 Psoriasis
2.4 Co-morbidities and Complications
2.5 Diagnosis, Scales and Grading
2.5.1 Atopic Dermatitis
2.5.2 Acne Vulgaris
2.5.3 Psoriasis
2.6 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation
2.6.1 Atopic Dermatitis
2.6.2 Acne Vulgaris
2.6.3 Psoriasis
2.7 Treatment
2.7.1 Topical Corticosteroids
2.7.2 Calcineurin Inhibitors
2.7.3 Retinoids
2.7.4 Systemic Immunosuppressive Agents
2.7.5 Biologics
2.7.6 Antihistamines
2.7.7 Hormonal Therapy
2.7.8 Moisturizers
3 Key Marketed Products
3.1 Overview
3.2 Humira (adalimumab) - AbbVie
3.3 Remicade (infliximab) - Johnson & Johnson
3.4 Enbrel (etanercept) - Amgen
3.5 Stelara (ustekinumab) - Johnson & Johnson
3.6 Neoral (cyclosporine) - Novartis
3.7 Protopic (tacrolimus) - Astellas Pharma
3.8 Cosentyx (Secukinumab) - Novartis
3.9 Dupixent (dupilumab) Sanofi and Regeneron
3.10 Taltz (ixekizumab) - Eli Lilly
3.11 Eucrisa (crisaborole) - Pfizer
3.12 Siliq (Brodalumab) - Valeant Pharmaceuticals
3.13 Elidel (pimecrolimus)
3.14 Elocon (mometasone furoate)
3.15 Differin (adapalene)
3.16 Metolate (methotrexate)
3.17 Clobex (clobetasol propionate)
3.18 Conclusion
4 Pipeline Landscape Assessment
4.1 Overview
4.2 Molecule Types in the Pipeline
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.5 Assessment of Key Pipeline Products
4.5 Conclusion
5 Multi-scenario Market Forecast to 2023
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Tumor Necrosis Factor-Alpha
5.3.2 Interleukins 1, 4, 5, 12, 17 and 23 and Receptors
5.3.3 Calcineurin
5.3.4 Glucocorticoid Receptors
5.3.5 Phosphodiesterase
6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 Novartis - Will Revenue from Cosentyx Continue to Increase in the Forecast Period?
6.1.2 AbbVie - Will Humira's Patent Expiry Lead to Loss of Market Leadership?
6.1.3 Johnson & Johnson - Guselkumab and Stelara Fail to Offset Revenue Lost from Remicade
6.1.4 Sanofi - High Revenue Growth from Dupixent Will See Sanofi's Revenue from the Dermatology Therapy Area Increase
6.1.5 Pfizer - Approval of Eucrisa to Drive Growth in the Dermatology Therapy Area
6.1.6 Celgene - Otezla Expected to Achieve Blockbuster Status in the Therapy Area
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis
7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type, Mechanism of Action and Value
7.1.4 Figures for Licensing Deals Valued Above $100m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type, Mechanism of Action and Value
7.2.4 Figures for Co-development Deals Valued Above $100m
8 Appendix
Companies Mentioned
- AbbVie
- Amgen
- Astellas Pharma
- Eli Lilly
- Johnson & Johnson
- Novartis
- Pfizer
- Sanofi and Regeneron
- Valeant Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/research/2hm9zm/global